The prescription DTC divide: who allows it and who does not
The most consequential single fact in healthcare advertising compliance is this: only the United States and New Zealand permit direct-to-consumer (DTC) advertising of prescription drugs to general audiences. Every other market in this group prohibits it in some form.
This divide shapes the entire channel strategy for any healthcare or pharma brand operating across multiple markets. A campaign built for the US audience (branded product name + condition + call-to-action) is a regulatory violation in Australia, Singapore, Canada, and Malaysia before a single pixel loads.
| Market | Regulator | Rx DTC to public | OTC to public | Testimonials (OTC) | Influencer posts |
|---|---|---|---|---|---|
| Singapore | HSA / MASA | Prohibited | Permitted (permitted indications only) | Restricted; governed by MASA | Treated as advertising; MASA applies |
| Australia | TGA / TGAC 2021 | Prohibited | Permitted (permitted indications only) | Allowed for some OTC/listed products; not Rx | Confirmed advertising under TGAC 2021 |
| Malaysia | MOH MAB / NPRA | Prohibited | Permitted (MAB pre-clearance required) | Subject to MAB approval | Treated as advertising requiring MAB review |
| United States | FDA / FTC / HHS | Permitted with required disclosures | Permitted (FTC substantiation) | Permitted with disclosure of material connection | FTC disclosure required; FDA risk info required for Rx |
| Canada | Health Canada / ASC | Prohibited (disease-awareness ads permitted) | Permitted (ASC pre-clearance for most categories) | Permitted for OTC; subject to ASC code | Subject to Food and Drugs Act re: Rx prohibition |
The geo-targeting risk for Rx campaigns
A US-legal Rx DTC campaign running on programmatic channels can serve impressions to users in Canada, Singapore, or Australia if geo-targeting is misconfigured or if a VPN-based user defeats the geo signal. For pharma brands running multi-market campaigns, country-level geo-fencing with a meaningful exclusion radius (not just IP-based) is a compliance requirement, not just a media efficiency choice.
Australia: TGA Therapeutic Goods Advertising Code 2021
The Therapeutic Goods Advertising Code 2021 (TGAC 2021) is the operative framework for healthcare and therapeutic goods advertising in Australia. It replaced the previous 2018 code and its 2019 update, and it extended significantly to cover influencer marketing.
The TGA's 2020 influencer clarification: The TGA confirmed that social media posts by influencers promoting therapeutic goods constitute advertising under the TGAC. This means influencer posts about complementary medicines, OTC products, medical devices, and any other therapeutic good are subject to the same content rules as broadcast or print advertising: permitted indications only, no testimonials for prescription products, mandatory qualifying statements for certain categories.
Prescription products: No advertising to the general public in any format. This includes celebrity posts, patient stories, disease-condition awareness posts that name or visually identify a specific prescription product, and digital or social distribution of branded prescription product information not prepared for healthcare professional audiences.
OTC medicines and listed complementary medicines: Permitted, with restrictions. Claims must align with the product's ARTG (Australian Register of Therapeutic Goods) registration. The advertising must include mandatory qualifying statements where required. Testimonials are permitted for listed medicines but must be genuine, the endorser must disclose payment, and comparative efficacy claims are not permitted.
Before-and-after imagery: Prohibited for therapeutic goods advertising under TGAC 2021 unless the TGA has specifically approved it for a product category.
TGA enforcement approach
The TGA's Advertising Compliance Unit actively monitors online advertising, including social media platforms. The TGA's Complaints Resolution Panel (CRP) receives consumer and competitor complaints about non-compliant advertising. The CRP can direct publication of a corrective advertisement, direct withdrawal of the non-compliant ad, and refer matters to the TGA for formal regulatory action. Healthcare brands operating in Australia should build a TGA advertising compliance review into their campaign approval workflow, separate from the general marketing sign-off.
The Australian Health Practitioner Regulation Agency (AHPRA) governs advertising by regulated healthcare practitioners (medical practitioners, nurses, psychologists). AHPRA's advertising guidelines prohibit testimonials from patients, misleading claims about qualifications or outcomes, and before-and-after photographs. Healthcare practitioners who engage in social media advertising must ensure their posts comply with both AHPRA guidelines and, where they involve therapeutic goods, the TGAC 2021.
Singapore: HSA and the Medicines Advertisement and Sale Act
Healthcare and pharmaceutical advertising in Singapore is governed primarily by the Health Sciences Authority (HSA) under the Health Products Act 2007 and the Medicines (Advertisement and Sale) Act (MASA).
Prescription medicines: Cannot be advertised to the public under MASA. This prohibition covers all consumer-facing channels: paid digital ads, organic social posts, influencer content, and any communication that promotes a named prescription medicine to a non-professional audience. Promotion to healthcare professionals (journal advertising, medical conference materials, HCP-targeted digital communications) is permitted with accurate, balanced information that is not misleading.
OTC medicines and health supplements: Permitted with restrictions. Claims must align with the product's approved therapeutic indications. HSA prohibits absolute claims ("cures", "eliminates", "prevents" unless specifically approved), and testimonials in formats that imply clinical outcomes. Health supplement advertising cannot make disease-treatment claims, which are reserved for registered medicines.
Social media and influencer content: Treated as advertising under MASA. An influencer who receives payment or product for a post about a health product is producing advertising and is subject to the same rules as the brand. The brand is responsible for ensuring influencer content complies.
Singapore Medical Council constraints on doctor marketing
The Singapore Medical Council's Ethical Code and Ethical Guidelines restrict how doctors can participate in advertising and promotion. Doctors cannot endorse specific health products for public promotion, cannot allow their names or images to be used in pharmaceutical advertising to the general public, and must not make unsubstantiated clinical claims in any public-facing communication. Healthcare brands that use clinical experts in their marketing must ensure the arrangement does not create a deemed endorsement in breach of SMC guidelines.
United States: FDA rules, HIPAA targeting, and the 2023 pixel bulletin
US healthcare marketing compliance operates across two overlapping frameworks: the FDA regulates what health content can say; HIPAA regulates what patient data can be used for marketing.
FDA prescription drug DTC: The US is one of two countries that permits branded DTC prescription drug advertising to general audiences. The requirements: broadcast and video ads must include a "major statement" verbally delivering the most important risks ("brief summary" equivalent in audio/video), include a call to see a doctor or pharmacist, and direct consumers to a full prescribing information source. Print ads require a "brief summary" of the prescribing information (risks, contraindications, precautions). The FDA issues Warning Letters to pharma companies for social media posts that omit risk information or that make superiority claims without substantiation.
The social media character-limit problem: The FDA's 2014 guidance on character-limited internet advertising (addressing Twitter-era posts) said that a post promoting a specific prescription drug must include risk information in the same post, not just a link. This guidance remains operative. For platforms that limit post length, this creates a structural compliance problem: fitting the product claim, material risk statement, and indication in a brief social post is often impossible for any prescription product with a significant risk profile.
HIPAA and the 2023 HHS pixel bulletin
In April 2023, the HHS Office for Civil Rights issued a bulletin stating that the use of tracking pixel technology (including Meta Pixel and Google Analytics) on HIPAA-covered entities' authenticated patient portal pages, scheduling pages, or condition-specific pages may constitute a HIPAA violation if the pixel collects and transmits protected health information to third parties without patient authorisation. This directly affects retargeting and conversion tracking for hospitals, health systems, and any covered entity that operates digital advertising through standard pixel implementations. Healthcare marketers should audit pixel placements on all pages that could expose PHI and review their BAA (Business Associate Agreement) arrangements with ad platform vendors.
HIPAA and custom audience targeting: A covered entity (hospital, insurer, health plan, many healthcare service organisations) cannot export patient records, appointment data, or diagnosis-linked identifiers to an advertising platform's custom audience tool without explicit patient authorisation for marketing use. This prohibition is specific: using email lists derived from patient billing records for Meta or Google custom audiences, without authorisation, is a HIPAA violation. The HIPAA marketing exception for treatment-related communications does not extend to advertising campaigns.
FTC health claims: The FTC applies its general advertising substantiation standard to health product claims, requiring competent and reliable scientific evidence. For claims about health products, the substantiation bar is typically randomised controlled trials or systematic reviews; anecdotal evidence or testimonials alone do not meet the FTC's substantiation standard for efficacy claims. The FTC's Endorsement Guides (2023 update) require influencers promoting health products to disclose material connections clearly, conspicuously, and in proximity to the endorsement.
Canada: Food and Drugs Act and OTC pre-clearance
Canada's pharmaceutical advertising rules are built around the Food and Drugs Act, with distinct tracks for prescription and over-the-counter medicines.
Prescription drug DTC prohibition: The Food and Drugs Act Section C.01.044 prohibits advertising prescription drugs to consumers. The prohibition is broad and covers brand-name mentions, indication mentions linked to a product name, and sponsored content that identifies a prescription product. The only consumer-facing content permitted for prescription drugs is disease-awareness advertising that does not name any specific product.
Canada's advertising standards framework has historically allowed a split between "reminder" advertising (brand name only, no indication, no image of condition) and "help-seeking" advertising (condition only, no brand name). Both were practised before regulatory guidance tightened. Current Health Canada guidance has narrowed what qualifies as compliant reminder or help-seeking content; any content that could identify a specific product while discussing a condition warrants pre-clearance review.
OTC medicine advertising: Permitted, subject to the Advertising Standards Canada (ASC) Code for Advertising Pharmaceuticals. ASC operates a pre-clearance service for OTC pharmaceutical advertising, and many broadcasters and major publishers require ASC pre-clearance before accepting OTC drug ads. Consumer Health Products Canada runs its own pre-clearance programme for health supplement and OTC product advertising. Digital-only campaigns that do not go through broadcast are technically not required to obtain pre-clearance, but pre-clearance is strongly advisable because it provides a defensible compliance record.
Quebec's Charter of the French Language applies a French language requirement to advertising directed at Quebec consumers. For digital campaigns targeting Canada, this means French language versions of ad creative for Quebec-targeted placements. The Commissioner of Official Languages and the Office de la langue francaise both have enforcement standing.
Malaysia: Ministry of Health MAB approval requirements
Malaysia's pharmaceutical advertising framework requires pre-approval for most medicine advertising before publication. The Medicine Advertisement Board (MAB), under the Ministry of Health Malaysia, administers this process.
Prescription medicines: Cannot be advertised to the public. This applies across all channels including digital and social media. Advertising to healthcare professionals follows separate rules and requires accurate, balanced information.
OTC medicines: Must be submitted to MAB for approval before advertising to the public. The Control of Drugs and Cosmetics Regulations 1984 and the Sales of Drugs Act 1952 establish the legal basis. MAB reviews claims, visuals, and messaging for accuracy, permitted indications, and compliance with restrictions on certain claim types. Campaigns that have not received MAB approval before publication are in violation, regardless of whether the medicine itself is legally registered.
Health supplements: Regulated separately by the National Pharmaceutical Regulatory Agency (NPRA). Health supplement claims must match the product's NPRA-approved indications. The distinction between a health supplement claim ("supports immune function") and a disease-treatment claim ("treats infection") is a common failure point; NPRA enforces this distinction actively.
Cosmeceuticals: Regulated under the Cosmetic Control Order 2008. Products marketed as cosmetics that also make medicinal claims cross into the pharmaceutical advertising domain, requiring MAB review and NPRA registration. The cosmeceutical category does not exist as a legal designation in Malaysia; a product is either a cosmetic or a drug, and the marketing claims determine which category applies.
Influencer and KOL marketing in Malaysia
Malaysian health and pharma brands use Key Opinion Leaders (KOLs) and social media influencers extensively. The MAB treats influencer posts about MAB-regulated products as advertising requiring prior approval. In practice, enforcement has been inconsistent but increasing. The safer approach: obtain MAB approval for the influencer content before publication, treating the post as a campaign execution rather than organic content. This means the influencer brief must specify the approved claims and approved visual elements.